Search

Displaying results 3941 - 3950 of 10000 in total
  1. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

  2. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage). … Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.

  3. Drug

    Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16711
    ApprovedInvestigational

    It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

  4. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. … However, there currently are no clinical indications for preferential use of ridogrel over aspirin.

  5. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Meglumine

    go.drugbank.com/drugs/DB09415
    ApprovedInvestigational

    Mixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 MLCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A Schedule IV drug in Canada.

    Synonyms: 17beta-Hydroxy-7beta,17-dimethylandrost-4-en-3-one
  8. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use, Topical Products for Joint and Muscular Pain
  9. Drug

    Thyroglobulin

    go.drugbank.com/drugs/DB01584
    ApprovedWithdrawn

    The active form of thyroxine, triiodothyronine, is produced both within the thyroid gland and periphery by 5'-deiodinase. … Patients with Hashimoto's thyroiditis or Graves' disease, frequently develop antibodies against thyroglobulin. Thyroglobulin is used to treat hypothyroidism.

  10. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.